FOLD Amicus Therapeutics, Inc.

5.34
+0.02  (0.38%)
Previous Close 5.32
Open 5.32
Price To book 2.25
Market Cap 760.02M
Shares 142,326,000
Volume 3,502,304
Short Ratio 7.06
Av. Daily Volume 3,474,190

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536767
  2. 8-K - Current report 17515778
  3. 8-K - Current report 162077775
  4. 8-K - Current report 162064654
  5. 8-K - Current report 162054937

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Additional trials required following feedback from FDA. Enrollment to commence 2017 with data due in 2019.
Migalastat HCl monotherapy (012)
Fabry Disease
Phase 3 top-line data due mid 2017.
SD-101
Epidermolysis Bullosa (EB)
Phase 1/2 preliminary data released December 8, 2016. Additional data due at 13th Annual WORLD Symposium February 13-17, 2017. Exact date TBC.
ATB200
Pompe Disease

Latest News

  1. Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook and Financial Guidance
  2. AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure,
  3. Huge Energy Trade Kicks Off 2017 Insider Buying: DCP Midstream, Och-Ziff Capital, TransEnterix, Amicus Therapeutics and More
  4. National Institute for Health and Care Excellence (NICE) Issues Final Positive Recommendation for Galafold™ (migalastat) for Fabry Disease in England
  5. 5 Stocks Insiders Love Right Now
  6. AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
  7. Amicus Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
  8. Abercrombie, OvaScience Slide Into Thursday’s 52-Week Low Club
  9. Amicus Therapeutics, Inc. (FOLD) Announces The Closure Of Its Senior Convertible Notes
  10. AMICUS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Def
  11. Amicus Therapeutics Announces Closing of Offering of Senior Convertible Notes and Exercise in Full of Option to Purchase Additional Notes
  12. Amicus Therapeutics Announces Closing of Offering of Senior Convertible Notes and Exercise in Full of Option to Purchase Additional Notes
  13. Today's Reports on Biotech Movers Ariad Pharmaceuticals and Amicus Therapeutics
  14. Abercrombie & Fitch, Hanesbrands Dip into Friday’s 52-Week Low Club
  15. AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  16. Amicus Therapeutics Announces Pricing of Offering of Convertible Senior Notes
  17. Amicus Therapeutics Announces Pricing of Offering of Convertible Senior Notes
  18. Amicus Therapeutics, Inc. (FOLD): Breaking Down The Raise
  19. Why Amicus Therapeutics Stock Is Sinking Today
  20. AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536767
  2. 8-K - Current report 17515778
  3. 8-K - Current report 162077775
  4. 8-K - Current report 162064654
  5. 8-K - Current report 162054937
  6. 8-K - Current report 162051760
  7. 8-K - Current report 162040426
  8. 8-K - Current report 162020422
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 161977609
  10. 8-K - Current report 161976666